undamentalytics Newsletter
Sign in

Longeveron Inc. income statement

In fiscal 2025, Longeveron Inc. reported revenue of $1.2m, down 49.9% on the year before, operating income of −$23.3m (a -1942.2% margin) and net income of −$22.7m, or −$1.29 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue6111211
Cost of revenue4110100
Gross profit2100211
Research and development379981212
Selling and marketing0111———
General and administrative310812101212
Operating income−4−17−18−21−17−23−24
Interest expense001————
Income tax——00000
Net income−4−17−19−21−16−23−23
Diluted EPS−$0.23−$0.90−$0.90−$10.22−$2.62−$1.29—
Diluted shares (average)16m19m21m2,173m9,411m17,577m—
EBITDA−4−17−17−20−16−22−23

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DARE vs LGVNLGVN vs STTKLGVN vs RNACLGVN vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Longeveron Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Longeveron Inc.